Lisa Wasemiller-Smith, MD
Obstetrics & Gynecology · Oklahoma City, OKNPI 1417954504
Payments from drug & device makers
Across 69 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$405
- Mayne Pharma Commercial LLC$132
- Amgen$82
- Avion Pharmaceuticals$67
- Scpharmaceuticals Inc.$67
- Pfizer$65
- plus $351 from 13 others
What the payments were for
- Food & beverage$1,13997%
- Education$111%
- Other$212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $405 |
| Mayne Pharma Commercial LLC | 7 | $132 |
| Amgen | 6 | $82 |
| Avion Pharmaceuticals | 4 | $67 |
| Scpharmaceuticals Inc. | 1 | $67 |
| Pfizer | 4 | $65 |
| Organon | 4 | $48 |
| Exact Sciences | 2 | $46 |
| Therapeuticsmd, Inc. | 3 | $44 |
| Bayer | 3 | $40 |
| Merck | 3 | $37 |
| Evofem Biosciences, Inc. | 2 | $27 |
| Vitrolife Inc. | 1 | $21 |
| Agile Therapeutics, Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $16 |
| Mylan Pharmaceuticals Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,170 in reported general payments places this provider in the 50th percentile of 396 obstetrics & gynecology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 109 | $3,228 |
| Estradiol (Twice Weekly)Estradiol | 18 | $2,529 |
| ProgesteroneProgesterone, Micronized | 46 | $1,913 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 24 | $635 |
| Spironolactone | 16 | $356 |
| Levothyroxine Sodium | 28 | $307 |
| Trazodone Hcl | 16 | $298 |
| Hydroxyzine Hcl | 16 | $254 |
| Buspirone Hcl | 11 | $156 |
| Medroxyprogesterone Acetate | 12 | $108 |
| Citalopram HbrCitalopram Hydrobromide | 17 | $91 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Oklahoma City
- Kathleen MooreOklahoma City$11.1M
- Tori OdanielOklahoma City$917K
- Beverly VavrickaOklahoma City$22K
- Monica ReidOklahoma City$20K
- Hoda MaaroufOklahoma City$15K
- Misty WaymanOklahoma City$13K
- Catherine HildebrandOklahoma City$12K
- Catherine GardnerOklahoma City$12K
- Kamal ShanbourOklahoma City$10K
- Darren GoffOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.